SM
SLNO

Sabby Management’s Soleno Therapeutics SLNO Stock Holding History

Sabby Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-35,328
Closed -$906K – 119
2018
Q4 		$906K Sell
35,328
-15,026
-30% -$439K 0.2% 37
2018
Q3 		$1.63M Sell
50,354
-2,043
-4% -$74.2K 0.21% 44
2018
Q2 		$1.84M Sell
52,397
-8,792
-14% -$258K 0.28% 47
2018
Q1 		$1.66M Buy
61,189
+182
+0.3% +$4.96K 0.2% 44
2017
Q4 		$1.65M Buy
+61,007
New +$1.76M 0.15% 56
2017
Q3 		– Sell
-3,308
Closed -$127K – 203
2017
Q2 		$127K Buy
3,308
+189
+6% +$8.76K 0.01% 192
2017
Q1 		$159K Buy
3,119
+732
+31% +$43.2K 0.01% 224
2016
Q4 		$145K Sell
2,387
-889
-27% -$61.6K 0.01% 256
2016
Q3 		$236K Sell
3,276
-3,407
-51% -$258K 0.01% 267
2016
Q2 		$581K Sell
6,683
-391
-6% -$35.7K 0.03% 205
2016
Q1 		$637K Buy
+7,074
New +$693K 0.03% 195

Other funds holding SLNO

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
TMC
Trellus Management Company Delray Beach, Florida $72.8M AUM 4.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Sabby Management's SLNO Position: Q1 2019 in Review

Sabby Management sold out of Soleno Therapeutics (SLNO) in Q1 2019, closing a stake of 35,328 shares — an estimated $906K sold.

Sabby Management first reported a position in SLNO in Q1 2016 and held it in 11 quarters. The position peaked at $1.84M in Q2 2018. 22 funds tracked by Wall St. Rank hold SLNO as of Q1 2019.

  • Sabby Management reported no remaining Soleno Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Sabby Management sold 35,328 Soleno Therapeutics shares in Q1 2019, an estimated $906K.
  • Sabby Management first reported a position in Soleno Therapeutics in Q1 2016 and held it in 11 quarters.
  • Sabby Management's Soleno Therapeutics position peaked at $1.84M in Q2 2018.
  • 22 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2019.

Based on Sabby Management's 13F filing for Q1 2019, filed 15 May 2019.